CN1342166A - 胰高血糖素样肽-1的类似物 - Google Patents
胰高血糖素样肽-1的类似物 Download PDFInfo
- Publication number
- CN1342166A CN1342166A CN99814185A CN99814185A CN1342166A CN 1342166 A CN1342166 A CN 1342166A CN 99814185 A CN99814185 A CN 99814185A CN 99814185 A CN99814185 A CN 99814185A CN 1342166 A CN1342166 A CN 1342166A
- Authority
- CN
- China
- Prior art keywords
- ala
- hglp
- seq
- pal
- aib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20683398A | 1998-12-07 | 1998-12-07 | |
US11118698P | 1998-12-07 | 1998-12-07 | |
US60/111,186 | 1998-12-07 | ||
US09/206,833 | 1998-12-07 | ||
PCT/US1999/028929 WO2000034332A1 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101410499A Division CN101108878B (zh) | 1998-12-07 | 1999-12-07 | 胰高血糖素样肽-1的类似物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1342166A true CN1342166A (zh) | 2002-03-27 |
CN100334109C CN100334109C (zh) | 2007-08-29 |
Family
ID=26808707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998141852A Expired - Fee Related CN100334109C (zh) | 1998-12-07 | 1999-12-07 | 胰高血糖素样肽-1的类似物 |
CN2007101410499A Expired - Fee Related CN101108878B (zh) | 1998-12-07 | 1999-12-07 | 胰高血糖素样肽-1的类似物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101410499A Expired - Fee Related CN101108878B (zh) | 1998-12-07 | 1999-12-07 | 胰高血糖素样肽-1的类似物 |
Country Status (21)
Country | Link |
---|---|
US (2) | US7368427B1 (zh) |
EP (2) | EP1992641A3 (zh) |
JP (3) | JP2002538081A (zh) |
KR (1) | KR100458748B1 (zh) |
CN (2) | CN100334109C (zh) |
AT (1) | ATE394423T1 (zh) |
AU (1) | AU770609B2 (zh) |
BR (1) | BR9916027A (zh) |
CA (1) | CA2352573C (zh) |
CZ (2) | CZ303120B6 (zh) |
DE (1) | DE69938669D1 (zh) |
DK (1) | DK1137666T5 (zh) |
ES (1) | ES2302390T3 (zh) |
HU (1) | HUP0104579A3 (zh) |
IL (2) | IL143481A0 (zh) |
NO (2) | NO330293B1 (zh) |
PL (3) | PL208751B1 (zh) |
PT (1) | PT1137666E (zh) |
RU (1) | RU2208015C2 (zh) |
TW (2) | TWI262925B (zh) |
WO (1) | WO2000034332A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715185A (zh) * | 2016-06-02 | 2019-05-03 | 印第安纳大学研究及科技有限公司 | 水溶性且化学稳定的胰高血糖素肽 |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903186B1 (en) | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
US7368427B1 (en) * | 1998-12-07 | 2008-05-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | GLP-1 analogues |
BR0113178A (pt) * | 2000-08-02 | 2004-04-06 | Theratechnologies Inc | Peptìdeos biológicos modificados com potência aumentada |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
WO2002022151A2 (en) | 2000-09-18 | 2002-03-21 | Osteometer Bio Tech A/S | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
CA2395165C (en) * | 2000-10-20 | 2012-05-22 | Mario Ehlers | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
EP2062593A3 (en) | 2000-12-01 | 2011-08-17 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive peptide |
AU2012202081B2 (en) * | 2001-07-31 | 2014-09-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 Exendin-4 peptide analogs and uses thereof |
DE60228972D1 (de) * | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
IL160917A0 (en) * | 2001-10-18 | 2004-08-31 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
PT1578778E (pt) | 2002-07-23 | 2011-03-07 | Ipsen Pharma | Análogos de grelina |
US7811989B2 (en) | 2003-01-17 | 2010-10-12 | Ipsen Pharma S.A.S. | Peptide YY analogs |
EP1594529B1 (en) * | 2003-02-19 | 2010-01-20 | Ipsen Pharma | Analogues of glp-1 |
WO2004087910A1 (ja) * | 2003-03-28 | 2004-10-14 | National Institute Of Agrobiological Sciences | 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質 |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
EP2210900A3 (en) * | 2003-12-16 | 2010-08-11 | Ipsen Pharma | Analogues of GLP-1 |
US7521527B2 (en) * | 2003-12-16 | 2009-04-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | GLP-1 pharmaceutical compositions |
JP2007537149A (ja) * | 2004-01-08 | 2007-12-20 | セラテクノロジーズ インコーポレイテッド | 長時間作用性のグルカゴン様ペプチド−1類似体 |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
DK1891105T3 (da) * | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
ES2628063T3 (es) * | 2007-01-05 | 2017-08-01 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos |
JP2010538069A (ja) * | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | エキセンディン−4およびエキセンディン−3の類似体 |
CN104447980A (zh) * | 2008-06-17 | 2015-03-25 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
WO2010076809A2 (en) * | 2008-12-29 | 2010-07-08 | Panacea Biotec Ltd | Glp-1 analogs and uses thereof |
JP2013540102A (ja) * | 2010-06-24 | 2013-10-31 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
US9278910B2 (en) | 2011-05-31 | 2016-03-08 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
US8778923B2 (en) | 2011-12-12 | 2014-07-15 | Receptos, Inc. | GLP-1 receptor modulators |
CN102584982B (zh) * | 2012-02-10 | 2014-02-05 | 深圳翰宇药业股份有限公司 | 一种纯化固相合成利拉鲁肽粗肽的方法 |
US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
SI3004155T1 (sl) * | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
CN103285379A (zh) * | 2013-06-09 | 2013-09-11 | 南方医科大学 | Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途 |
EP3008056B8 (en) | 2013-06-11 | 2021-03-03 | Receptos Llc | Novel glp-1 receptor modulators |
CN107074820B (zh) | 2014-07-25 | 2021-05-18 | 赛尔基因第二国际有限公司 | Glp-1受体调节剂 |
JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
AU2015360364B2 (en) | 2014-12-10 | 2020-04-30 | Receptos Llc | GLP-1 receptor modulators |
CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
NZ743474A (en) | 2015-12-23 | 2023-03-31 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
CN109942696A (zh) * | 2017-12-21 | 2019-06-28 | 中国药科大学 | 长效化胰高血糖素样肽-1(glp-1)类似物及其应用 |
CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1539498A (en) | 1925-05-26 | And fifteen | ||
JP3262329B2 (ja) * | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
BR9306551A (pt) * | 1992-06-15 | 1998-09-15 | Pfizer | Derivados de peptídeo do tipo glucagona e de insulinotropina |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
WO1997029180A1 (en) * | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
WO1998043658A1 (en) * | 1997-03-31 | 1998-10-08 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
EP1056774A1 (en) | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US6903186B1 (en) | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
US7368427B1 (en) * | 1998-12-07 | 2008-05-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | GLP-1 analogues |
EP1239871A1 (en) | 1999-11-12 | 2002-09-18 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
-
1999
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 AT AT99960657T patent/ATE394423T1/de active
- 1999-12-07 CN CNB998141852A patent/CN100334109C/zh not_active Expired - Fee Related
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/ja active Pending
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
- 1999-12-07 ES ES99960657T patent/ES2302390T3/es not_active Expired - Lifetime
- 1999-12-07 IL IL14348199A patent/IL143481A0/xx unknown
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/cs not_active IP Right Cessation
- 1999-12-07 PT PT99960657T patent/PT1137666E/pt unknown
- 1999-12-07 PL PL385112A patent/PL208751B1/pl unknown
- 1999-12-07 DK DK99960657T patent/DK1137666T5/da active
- 1999-12-07 PL PL393611A patent/PL393611A1/pl unknown
- 1999-12-07 PL PL349609A patent/PL205713B1/pl unknown
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/ko not_active IP Right Cessation
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/hu unknown
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/ru not_active IP Right Cessation
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/pt not_active IP Right Cessation
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/zh not_active Expired - Fee Related
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/cs not_active IP Right Cessation
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en active Application Filing
- 1999-12-07 DE DE69938669T patent/DE69938669D1/de not_active Expired - Lifetime
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
-
2000
- 2000-01-07 TW TW088121393A patent/TWI262925B/zh not_active IP Right Cessation
- 2000-01-07 TW TW095106593A patent/TWI339208B/zh not_active IP Right Cessation
-
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/no not_active IP Right Cessation
-
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/ja active Pending
-
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
-
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/ja active Pending
-
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/no not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715185A (zh) * | 2016-06-02 | 2019-05-03 | 印第安纳大学研究及科技有限公司 | 水溶性且化学稳定的胰高血糖素肽 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100334109C (zh) | 胰高血糖素样肽-1的类似物 | |
CN100540566C (zh) | 胰高血糖素样肽-1的类似物 | |
CN1137898C (zh) | 甲状旁腺素的类似物 | |
JP2010174016A (ja) | Glp−1類似体 | |
CN1935839B (zh) | 胰高血糖素样肽-1的类似物 | |
CN1683408A (zh) | 胰高血糖素样肽类似物、其组合物及其使用方法 | |
MXPA01005763A (en) | Glp-1 analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: IPSEN MEDICINE CO.,LTD. Free format text: FORMER NAME: SOD CONSEILS RECH APPLIC |
|
CP03 | Change of name, title or address |
Address after: Paris, FRA Co-patentee after: Tulane Educational Fund Management Committee Patentee after: Beaufour Ipsen Pharma Address before: Paris, FRA Co-patentee before: Tulane Educational Fund Management Committee Patentee before: Association of research and Applied Sciences Limited by Share Ltd |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: France 92650 - Boulogne Billancourt, Georges Plantagenet pier No. 65 Co-patentee after: Tulane Educational Fund Management Committee Patentee after: Beaufour Ipsen Pharma Address before: Paris, FRA Co-patentee before: Tulane Educational Fund Management Committee Patentee before: Beaufour Ipsen Pharma |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070829 Termination date: 20121207 |